Emerging vaccine strategies against the incessant pneumococcal disease.
Emerging vaccine strategies against the incessant pneumococcal disease.
复制标题
DOI：
10.1038/s41541-023-00715-w
复制
发表时间：
2023-08-17
期刊：
影响因子：
9.2
通讯作者：
Avci, Fikri Y.
中科院分区：
文献类型：
--
作者：
Duke, Jeremy A.;Avci, Fikri Y.
由于全球疫苗接种计划，由病原体肺炎链球菌（Spn）感染引起的侵袭性肺炎球菌病（IPD）的发病率数十年来一直呈下降趋势。尽管观察到临床上的成功，疾病控制中心（CDC）报告说，持续的全球负担的S。每年将有数百万人感染肺炎，病死率徘徊在5%左右。因此，当务之急是继续开发新的Spn疫苗接种策略，以利用免疫学洞察力并增加所提供的保护程度。正如世界卫生组织（世卫组织）所强调的那样，扩大已在临床环境中获得的疫苗的实施也至关重要。本文综述了现有肺炎球菌疫苗引发的免疫机制，并概述了目前和即将采用的临床策略。我们强调了血清型选择性和使用肺炎球菌衍生蛋白作为替代疫苗抗原的相关挑战。
The incidence of invasive pneumococcal disease (IPD) caused by infection with the pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due to worldwide vaccination programs. Despite the clinical successes observed, the Center for Disease Control (CDC) reports that the continued global burden of S. pneumoniae will be in the millions each year, with a case-fatality rate hovering around 5%. Thus, it is a top priority to continue developing new Spn vaccination strategies to harness immunological insight and increase the magnitude of protection provided. As emphasized by the World Health Organization (WHO), it is also crucial to broaden the implementation of vaccines that are already obtainable in the clinical setting. This review focuses on the immune mechanisms triggered by existing pneumococcal vaccines and provides an overview of the current and upcoming clinical strategies being employed. We highlight the associated challenges of serotype selectivity and using pneumococcal-derived proteins as alternative vaccine antigens.
登录
查看更多内容
影响因子：
3.7
作者：
Park IH;Geno KA;Sherwood LK;Nahm MH;Beall B
通讯作者：
Beall B
影响因子：
3.1
作者：
BRILES, DE;CRAIN, MJ;YOTHER, J
通讯作者：
YOTHER, J
影响因子：
2.3
作者：
Casadevall, Arturo;Pirofski, Liise-anne
通讯作者：
Pirofski, Liise-anne
影响因子：
--
作者：
Chen, Austen;Mann, Beth;Paton, James C.
通讯作者：
Paton, James C.
影响因子：
14.8
作者：
通讯作者：
--